Increased mitogenic activity of scleroderma serum: inhibitory effect of human recombinant interferon-gamma (Q33566816)

28 July 2017

title

Increased mitogenic activity of scleroderma serum: inhibitory effect of human recombinant interferon-gamma (English)

1 reference

28 July 2017

Bryckaert M

1

1 reference

28 July 2017

Fontenay M

2

1 reference

28 July 2017

Lioté F

3

1 reference

28 July 2017

Bellucci S

4

1 reference

28 July 2017

Carriou R

5

1 reference

28 July 2017

Tobelem G

6

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 November 1994

1 reference

Annals of the Rheumatic Diseases

28 July 2017

published in

1 reference

28 July 2017

volume

53

1 reference

28 July 2017

issue

11

1 reference

28 July 2017

page(s)

776-779

1 reference

Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1005462

Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1005462

Inhibition of excessive scleroderma fibroblast collagen production by recombinant gamma-interferon. Association with a coordinate decrease in types I and III procollagen messenger RNA levels

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1005462

Recombinant interferon-gamma in the treatment of systemic sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1005462

Alpha interferon-2a (Roferon-A) in the treatment of diffuse cutaneous systemic sclerosis: a pilot study. UK Systemic Sclerosis Study Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1005462

Endothelial injury in scleroderma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1005462

Cytotoxicity of sera from patients with scleroderma. Effects on human endothelial cells and fibroblasts in culture

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1005462

Endothelial injury in scleroderma. A protease mechanism

31 October 2018

1 reference

12 December 2020

Interferon-alpha and interferon-gamma reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in culture

1 reference

12 December 2020

Recombinant interferon-gamma inhibits the mitogenic effect of platelet-derived growth factor at a level distal to the growth factor receptor

1 reference

12 December 2020

Increased expression of platelet-derived growth factor type b receptors in the skin of patients with systemic sclerosis

1 reference

12 December 2020

Increased Plasma Levels of Platelet-Derived Growth Factor Activity in Patients with Progressive Systemic Sclerosis

1 reference

12 December 2020

Letters: Fibroblasts from a patient with scleroderma reveal abnormal metabolism

1 reference

12 December 2020

Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma

1 reference

12 December 2020

Identifiers

DOI

10.1136/ARD.53.11.776

1 reference

28 July 2017

1 reference

28 July 2017

1 reference